MeSH D007945 - lymphoid leukemia
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
D007945:Â
Lymphoid leukemia
Events Timeline
Commercial
Company Name | Drug Name | Trade Name | Patent Expires | Approval Date | Revenue | Period |
|---|---|---|---|---|---|---|
| Teva | Imatinib | Imatinib |  | 2016-08-04 |  |  |
| Imatinib | Imatinib Teva |  | 2013-01-07 |  |  | |
| Imatinib | Imatinib Teva B.V |  | 2017-11-15 |  |  | |
| Mylan | Imatinib | Imatinib |  | 2017-06-21 |  |  |
| Bendamustine | Bendamustine |  | 2023-04-28 |  |  | |
| Roche | Obinutuzumab | Gazyvaro |  | 2014-07-22 |  |  |
| Rituximab | MabThera |  | 1998-06-02 |  |  | |
| Sandoz | Rituximab | Rixathon |  | 2017-06-15 |  |  |
| Rituximab | Riximyo |  | 2017-06-15 |  |  | |
| AbbVie | Venetoclax | Venclexta | 2030-05-26 | 2016-04-11 | $2,288 M | Y2023 |
| Venetoclax | Venclyxto |  | 2016-12-04 |  |  | |
| Novartis | Imatinib | Gleevec |  | 2001-05-10 | $887 M | Q2/20-Q2/23 |
| Imatinib | Glivec |  | 2001-11-07 |  |  | |
| Pfizer | Rituximab | Ruxience |  | 2019-07-23 | $390 M | Y2023 |
| Dr Reddys Laboratories | Bendamustine | Bendamustine |  | 2022-12-07 |  |  |
| Imatinib | Imatinib |  | 2018-08-13 |  |  |
1
2
3
4
5
>
Clinical Trials
Historical Success Rate
Phase 1
39%13/33
Phase 2
10%4/40
Phase 3
88%15/17
Approved: 13Overall Success rate: 3%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Drug Name |
|---|---|---|---|---|---|
1
2
3
4
>
© 2020-2023 Collaborative Drug Discovery Inc. (CDD) | Terms of Use